Direct systemic delivery
clinical
0 views
Prostamax
Prostamax (Lys-Glu-Asp-Pro/KEDP) is a synthetic tetrapeptide bioregulator from the Khavinson peptide family that demonstrates prostate-specific tissue effects.
Overview
Prostamax (Lys-Glu-Asp-Pro/KEDP) is a synthetic tetrapeptide bioregulator from the Khavinson peptide family that demonstrates prostate-specific tissue effects. Preclinical research shows anti-inflammatory and tissue-protective properties in chronic prostatitis models, with emerging interest in epigenetic chromatin regulation and anti-aging applications. Human clinical trial data remains limited.
Last reviewed: 2026-08-18
Identity & Aliases
Also known as
ProstamaxKEDP peptideLys-Glu-Asp-ProKhavinson bioregulator tetrapeptide
Status: Research compound - human clinical trial data not yet published
Full composition (formula, molecular weight, sequence) in Quick Facts →
Research Areas
Prostate-tissue bioregulationShort-peptide (Khavinson) bioregulatorsChronic prostatitis (preclinical)
Available Evidence
Animal
Preclinical work (largely Russian-language, Khavinson school) reports prostate-tissue-specific effects, including anti-inflammatory and tissue-protective actions in models of chronic prostatitis.
In Vitro
Cell studies report the KEDP tetrapeptide modulates proliferation and gene expression in prostate cell lines, but published detail is limited.
Uncertain
Prostate-health, anti-aging, and epigenetic-regulation claims are not supported by robust clinical evidence. The name 'Prostamax' also belongs to unrelated herbal prostate supplements, causing record-level confusion.
Benefits & Effects
optimal bioavailability for prostate tissue targeting
clinical
established preclinical protocols
clinical
No side effects data available yet.
This peptide may have limited safety data.
Limitations & Open Questions
No indexed clinical trials, no pharmacokinetic data, and little independent replication. Evidence rests on limited Russian-language bioregulator research and vendor material; readers should treat prostate-benefit claims as unproven and note the name collision with commercial herbal supplements.
Reported Research Dosing
Reported values from research literature and community protocols. Educational reference only — not a dosing recommendation or medical advice.
0.5-1mg daily
Route: Injectable
Half-life: 20-40 minutes plasma
Research Protocols
Prostate Health Support
- Dose
- 0.5-1mg daily
- Frequency
- Once daily
- Route
- Subcutaneous injection
Anti-Aging Protocol
- Dose
- 0.75mg daily
- Frequency
- Once daily for 10-20 days
- Route
- Subcutaneous injection
Preclinical Reference (Rat Model)
- Dose
- 20 μg/kg
- Frequency
- Daily for 15 days
- Route
- Intramuscular
Research protocols are for educational purposes only. Always consult qualified medical professionals.
Frequently Asked Questions
Is Prostamax clinically proven for prostate health?
No. No published human trials exist for the KEDP peptide; prostate-benefit claims are preclinical or unproven.
Is the peptide Prostamax the same as the supplement sold in stores?
No. The peptide Prostamax (KEDP) is distinct from herbal 'Prostamax' supplements; the shared name causes confusion.
Research Citations
1
Benign Prostatic Hyperplasia Model (2014)
(2014)
2
Chronic Aseptic Prostatitis - Rat Model (2013)
(2013)
3
Deheterochromatinization in Aging (2012)
(2012)
Related Resources
Quick Facts
Molecular Weight
487.50
Mechanism
Subcutaneous injection provides systemic circulation for tissue-specific bioregulation of prostate gland cells
Safety Information
Human clinical trial data not yet published - dosing extrapolated from preclinical models. Possible mild injection site reactions (redness, swelling). Rare reports of mild digestive discomfort or headache. Contraindicated when active prostate malignancy exists - theoretical concern for tumor growth stimulation. Not recommended during pregnancy or lactation. Quality sourcing critical - verify purity and avoid contaminated products.
Citations
31.Benign Prostatic Hyperplasia Model (2014)
(2014)
2.Chronic Aseptic Prostatitis - Rat Model (2013)
(2013)
3.Deheterochromatinization in Aging (2012)
(2012)